Ginsberg A M
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.
Public Health Rep. 1998 Mar-Apr;113(2):128-36.
One in every three people on Earth is believed to be infected with Mycobacterium tuberculosis, leading to seven to eight million cases of active tuberculosis (TB) per year and approximately three million deaths annually. this epidemic, like those of most infectious diseases, creates scientific challenges and opportunities as it raises the demand for public health solutions. The currently available weapons for fighting TB are inadequate. The ultimate goal of biomedical TB research is to lessen the public health burden of this disease by developing improved diagnostic, therapeutic, and intervention strategies. Achieving this goal requires a base of knowledge about the biology of M. tuberculosis and related mycobacteria, their interactions with human and animal hosts, and the nature of an effective host-protective immune response. TB researchers are applying this accumulating base of knowledge to developing rapid, easy-to-use diagnostic assays appropriate for low-as well as high-income countries, improving the current complicated therapeutic regimen, identifying potential new drugs to combat multidrug-resistant TB, and creating more effective vaccines.
据信,地球上每三个人中就有一人感染结核分枝杆菌,每年导致700万至800万例活动性结核病(TB)病例,每年约有300万人死亡。与大多数传染病一样,这种流行病带来了科学挑战和机遇,因为它增加了对公共卫生解决方案的需求。目前用于抗击结核病的手段并不充足。生物医学结核病研究的最终目标是通过开发改进的诊断、治疗和干预策略,减轻这种疾病对公共卫生的负担。要实现这一目标,需要掌握关于结核分枝杆菌和相关分枝杆菌的生物学知识、它们与人类和动物宿主的相互作用,以及有效的宿主保护性免疫反应的性质。结核病研究人员正在利用这一不断积累的知识基础,开发适用于低收入和高收入国家的快速、易用的诊断检测方法,改进当前复杂的治疗方案,确定对抗耐多药结核病的潜在新药,并研发更有效的疫苗。